Results 181 to 190 of about 123,533 (244)

Management and long‐term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia‐related neuropathy: A single‐centre experience

British Journal of Haematology, EarlyView.
In this 28‐patient retrospective cohort, rituximab‐based regimens for IgM‐related neuropathy yielded significant, sustained functional and neurological improvements over a 2‐year follow‐up. Furthermore, reductions in serum IgM levels correlated with improved Inflammatory Neuropathy Cause and Treatment disability scores, highlighting the long‐term ...
Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Sotirios Manganas, Foteini Theodorakakou, Irene Solia, Evangelos Eleutherakis‐Papaiakovou, Ilias Katsadouros, Panagiotis Boutsikos, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios‐Athanasios Dimopoulos   +15 more
wiley   +1 more source

Rhizoma Dioscoreae Nipponicae attenuates airway remodeling and angiogenesis-related changes in asthma with altered mTOR/4EBP1/HIF-1α/VEGF pathway markers. [PDF]

World Allergy Organ J
Zhou X, Wang Z, Zheng S.
europepmc   +1 more source

Real‐World Outcomes of Omalizumab for Chronic Spontaneous Urticaria in a New Zealand Regional Dermatology Service

Australasian Journal of Dermatology, EarlyView.
Jeffrey Lee, Karen Koch
wiley   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Steroid-sparing strategies in polymyalgia rheumatica: a systematic review and meta-analysis of tocilizumab with practical guidance for tapering. [PDF]

BMC Rheumatol
Bungish MK, Mohsan M, Farooq H, Shaukat MT, Rehman WU, Murtaza AT, Fatima A, Akhtar MH, Farooq H, Mufti A, Sarwar S, Rehman AU, Mohsin A.   +12 more
europepmc   +1 more source

Comparison of outcomes after DA‐EPOCH‐R or GMALL high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort

British Journal of Haematology, EarlyView.
In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T. Prochazka   +4 more
wiley   +1 more source

Hypothesis-Generating Analysis of Four Immunosuppressive Regimens After Simultaneous Pancreas-Kidney Transplantation Using the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

Cureus
Ogura T, Shiraishi C, Urawa A.
europepmc   +1 more source

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

Allergy, EarlyView.
Jaime Bernaola, José Antonio Cañas, Álvaro Arranz‐Fragua, José Manuel Rodrigo‐Muñoz, Daniel Rodríguez‐González, Antonio Serrano‐Santiago, Gema Guillén‐Sánchez, Alma Martínez Fernández, Marcela Valverde‐Monge, Diana Betancor, Erwin Javier Pinillos‐Robles, Claudia Rodríguez‐Busto, María Jesús Rodríguez‐Nieto, Joaquín Sastre, Victoria del Pozo   +14 more
wiley   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source